نتایج جستجو برای: dasatinib

تعداد نتایج: 1954  

Journal: :Molecular cancer therapeutics 2015
Lisa Christiansson Stina Söderlund Sara Mangsbo Henrik Hjorth-Hansen Martin Höglund Berit Markevärn Johan Richter Leif Stenke Satu Mustjoki Angelica Loskog Ulla Olsson-Strömberg

Immune escape mechanisms promote tumor progression and are hurdles of cancer immunotherapy. Removing immunosuppressive cells before treatment can enhance efficacy. Tyrosine kinase inhibitors (TKI) may be of interest to combine with immunotherapy, as it has been shown that the inhibitor sunitinib reduces myeloid suppressor cells in patients with renal cell carcinoma and dasatinib promotes expans...

Journal: :Blood 2008
Andrew E Schade Gary L Schieven Robert Townsend Anna M Jankowska Vojkan Susulic Rosemary Zhang Hadrian Szpurka Jaroslaw P Maciejewski

Dasatinib is an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity, we hypothesized this agent could provide a novel route of immunomodulation via targeted inhibition of antigen...

Journal: :Blood 2007
Oliver Ottmann Hervé Dombret Giovanni Martinelli Bengt Simonsson Francois Guilhot Richard A Larson Giovanna Rege-Cambrin Jerald Radich Andreas Hochhaus Anne Marie Apanovitch Ashwin Gollerkeri Steven Coutre

Patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL) have a rapid disease course and a poor prognosis. Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL. We present the interim results of a phase 2 study designed to furth...

2018
Mario Tiribelli Massimiliano Bonifacio Gianni Binotto Alessandra Iurlo Francesca Cibien Elena Maino Anna Guella Gianluca Festini Claudia Minotto Ercole De Biasi Federico De Marchi Luigi Scaffidi Luca Frison Cristina Bucelli Marta Medeot Elisabetta Calistri Rosaria Sancetta Manuela Stulle Nicola Orofino Mauro Krampera Filippo Gherlinzoni Gianpietro Semenzato Giovanni Pizzolo Achille Ambrosetti Renato Fanin

Second-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients failing imatinib. Direct comparisons between dasatinib and nilotinib are lacking, and few studies addressed the dynamics of deep molecular response (DMR)...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2008
Lisa J Christopher Donghui Cui Wenying Li Anthony Barros Vinod K Arora Haiying Zhang Lifei Wang Donglu Zhang James A Manning Kan He Anthony M Fletcher Marc Ogan Michael Lago Samuel J Bonacorsi W Griffith Humphreys Ramaswamy A Iyer

This study describes the in vitro metabolism of [(14)C]dasatinib in liver tissue incubations from rat, monkey, and human and the in vivo metabolism in rat and monkey. Across species, dasatinib underwent in vitro oxidative metabolism to form five primary oxidative metabolites. In addition to the primary metabolites, secondary metabolites formed from combinations of the oxidative pathways and con...

Journal: :Blood 2009
Marie-Pierre Gratacap Valérie Martin Marie-Cécile Valéra Sophie Allart Cédric Garcia Pierre Sié Christian Recher Bernard Payrastre

Dasatinib is an oral potent adenosine triphosphate (ATP)-competitive inhibitor of BCR-ABL, cKIT, platelet-derived growth factor receptor, and SRC family kinases (SFKs), which has demonstrated high efficiency in patients with imatinib-resistant chronic myelogenous leukemia. Here, we show that dasatinib weakly affects platelet activation by thrombin or adenosine diphosphate but is a potent inhibi...

2018
Takashi Kumagai Chiaki Nakaseko Kaichi Nishiwaki Chikashi Yoshida Kazuteru Ohashi Naoki Takezako Hina Takano Yasuji Kouzai Tadashi Murase Kosei Matsue Satoshi Morita Junichi Sakamoto Hisashi Wakita Hisashi Sakamaki Koiti Inokuchi

Tyrosine kinase inhibitors (TKI) improve the prognosis of patients with chronic myelogenous leukemia (CML) by inducing substantial deep molecular responses (DMR); some patients have successfully discontinued TKI therapy after maintaining DMR for ≥1 year. In this cessation study, we investigated the optimal conditions for dasatinib discontinuation in patients who maintained DMR for ≥2 years. Thi...

2014
Pierre Vanden Borre Viswanath Gunda David G. McFadden Peter M. Sadow Shohreh Varmeh Maria Bernasconi Sareh Parangi

Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective treatments. Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models of thyroid cancer, however, neither drug induces notable apoptosis. Here we report that the SRC-inhibitor dasatinib further sensitizes BRAFV600E-positive thyroid cancer cells to the BRAFV600E-inhibitor PLX4720. Combine...

Journal: :Journal of the American Society of Nephrology : JASN 2017
Chengguo Wei Li Li Madhav C Menon Weijia Zhang Jia Fu Brian Kidd Karen L Keung Christopher Woytovich Ilana Greene Wenzhen Xiao Fadi Salem Zhengzi Yi John Cijiang He Joel T Dudley Barbara Murphy

Renal fibrosis is the common pathway of progression for patients with CKD and chronic renal allograft injury (CAI), but the underlying mechanisms remain obscure. We performed a meta-analysis in human kidney biopsy specimens with CAI, incorporating data available publicly and from our Genomics of Chronic Renal Allograft Rejection study. We identified an Src family tyrosine kinase, hematopoietic ...

2016
Yu Jin Kim Sungyoul Hong Minjung Sung Min Jeong Park Kyungsoo Jung Ka-Won Noh Doo-Yi Oh Mi-Sook Lee Ensel Oh Young Kee Shin Yoon-La Choi

Therapies targeting SRC family kinases (SFKs) have shown efficacy in treating non-small cell lung cancer (NSCLC). However, recent clinical trials have found that the SFK inhibitor dasatinib is ineffective in some patient cohorts. Regardless, dasatinib treatment may benefit some NSCLC patient subgroups. Here, we investigated whether expression of LYN, a member of the SFK family, is associated wi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید